Cytokinetics Inc Stock Price, News & Analysis

Cytokinetics (Nasdaq: CYTK) has announced that it will release its second quarter 2024 financial results on August 8, 2024, at 4:00 PM Eastern Time. Following the announcement, the company's senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results, as well as the company's future outlook.

Investors and interested parties can access the conference call through a simultaneous webcast available on the Investors & Media section of Cytokinetics' website. Additionally, participants can join the call via telephone by registering in advance through a provided link. An archived replay of the webcast will be accessible on the company's website for twelve months after the event.

Cytokinetics (CYTK) announced seven upcoming presentations at the European Society of Cardiology Congress 2024, including four Late Breaking Clinical Trial presentations on aficamten. The presentations will cover:

1. Effect of aficamten on patient-reported health status in obstructive hypertrophic cardiomyopathy (SEQUOIA-HCM)
2. Impact of aficamten on echocardiographic cardiac structure and function
3. Effect of aficamten on structure and function (SEQUOIA-HCM CMR Substudy)
4. Safety and outcomes of standard of care medications withdrawal (FOREST-HCM Trial)
5. Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy (SEQUOIA-HCM)
6. Integrated safety analysis of aficamten
7. Menopausal status and clinical outcomes in women with heart failure (GALACTIC-HF Trial)

The congress takes place in London, UK from August 30 to September 2, 2024.

Cytokinetics announced inducement grants under Nasdaq Listing Rule 5635(c)(4) for 10 new employees whose employment began in June 2024. These grants include stock options for 48,453 shares at an exercise price of $54.18 per share, 31,460 restricted stock units (RSUs), and 5,537 performance stock units (PSUs). The RSUs will vest over three years, while stock options will vest over four years with a 10-year term. PSUs are tied to performance goals, vesting based on achievement certifications by the Compensation and Talent Committee. These awards are leveraged to attract and retain new talent.

Cytokinetics announced the initiation of a Phase 1 study to evaluate the pharmacokinetics, safety, and tolerability of aficamten in healthy Japanese and Caucasian participants.

This double-blind, randomized, placebo-controlled trial will involve 70 participants split into four cohorts.

The study aims to gather essential data for potential approval in Japan and to complement ongoing global clinical development and regulatory submissions in the U.S. and Europe, expected later this year.

Cytokinetics announced inducement grants under Nasdaq Listing Rule 5635(c)(4) on June 4, 2024. The company granted stock options, RSUs, and PSUs to its new CFO, Sung H. Lee, and 12 other employees. Sung H. Lee received 53,417 stock options, 34,684 RSUs, and 34,426 PSUs, while the other employees were granted 93,525 stock options, 60,724 RSUs, and 40,610 PSUs. The RSUs will vest over three years, and stock options will vest over four years with an exercise price of $48.51 per share. PSUs will vest based on achieving performance goals. All grants are inducements for employment.

Cytokinetics (Nasdaq: CYTK) announced its participation in two major healthcare investor conferences in June 2024.

Robert I. Blum, President and CEO, alongside Andrew Callos, EVP and Chief Commercial Officer, will join fireside chats at both events.

The Jefferies Global Healthcare Conference occurs on June 5 at 2:00 PM ET in New York, while the 45th Annual Goldman Sachs Healthcare Conference will be on June 10 at 11:20 AM ET in Miami Beach.

Live webcasts of these chats will be accessible via Cytokinetics' website, with replays available for 90 days post-event.

Cytokinetics announced the closing of its public offering of 9,803,922 shares of common stock at $51.00 per share. The offering raised approximately $500 million before expenses. The offering was managed by J.P. Morgan, Goldman Sachs & Co. , and Morgan Stanley. The securities were offered under a shelf registration statement filed in November 2022 with the SEC, which is now effective.

Cytokinetics announced the pricing of a public offering of 9,803,922 shares of its common stock at $51.00 per share.

Expected gross proceeds are approximately $500 million before underwriting discounts and other expenses.

The offering is set to close on May 28, 2024, subject to customary conditions.

The company has also given underwriters a 30-day option to buy an additional 1,470,588 shares at the public offering price, less underwriting discounts and commissions.

J.P. Morgan, Goldman Sachs, and Morgan Stanley are acting as joint book-running managers for the offering.

Cytokinetics announced a proposed public offering of approximately $500 million of common stock, subject to market conditions.

The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering.

J.P. Morgan, Goldman Sachs & Co. , and Morgan Stanley will act as joint book-running managers.

The securities will be offered under a shelf registration statement filed with the SEC on November 18, 2022, which is effective.

A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on their website.

This announcement does not constitute an offer to sell or a solicitation of an offer to buy the securities.